Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

440 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Specific human cytomegalovirus signature detected in NK cell metabolic changes post vaccination.
Woods E, Zaiatz-Bittencourt V, Bannan C, Bergin C, Finlay DK, Hoffmann M, Brown A, Turner B, Makvandi-Nejad S, Vassilev V, Capone S, Folgori A, Hanke T, Barnes E, Dorrell L, Gardiner CM; PEACHI Consortium. Woods E, et al. Among authors: hanke t. NPJ Vaccines. 2021 Sep 28;6(1):117. doi: 10.1038/s41541-021-00381-w. NPJ Vaccines. 2021. PMID: 34584101 Free PMC article.
A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.
Mwau M, Cebere I, Sutton J, Chikoti P, Winstone N, Wee EG, Beattie T, Chen YH, Dorrell L, McShane H, Schmidt C, Brooks M, Patel S, Roberts J, Conlon C, Rowland-Jones SL, Bwayo JJ, McMichael AJ, Hanke T. Mwau M, et al. Among authors: hanke t. J Gen Virol. 2004 Apr;85(Pt 4):911-919. doi: 10.1099/vir.0.19701-0. J Gen Virol. 2004. PMID: 15039533 Clinical Trial.
Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers.
Cebere I, Dorrell L, McShane H, Simmons A, McCormack S, Schmidt C, Smith C, Brooks M, Roberts JE, Darwin SC, Fast PE, Conlon C, Rowland-Jones S, McMichael AJ, Hanke T. Cebere I, et al. Among authors: hanke t. Vaccine. 2006 Jan 23;24(4):417-25. doi: 10.1016/j.vaccine.2005.08.041. Epub 2005 Aug 24. Vaccine. 2006. PMID: 16176847 Clinical Trial.
Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine.
Dorrell L, Yang H, Ondondo B, Dong T, di Gleria K, Suttill A, Conlon C, Brown D, Williams P, Bowness P, Goonetilleke N, Rostron T, Rowland-Jones S, Hanke T, McMichael A. Dorrell L, et al. Among authors: hanke t. J Virol. 2006 May;80(10):4705-16. doi: 10.1128/JVI.80.10.4705-4716.2006. J Virol. 2006. PMID: 16641264 Free PMC article.
Design and pre-clinical evaluation of a universal HIV-1 vaccine.
Létourneau S, Im EJ, Mashishi T, Brereton C, Bridgeman A, Yang H, Dorrell L, Dong T, Korber B, McMichael AJ, Hanke T. Létourneau S, et al. Among authors: hanke t. PLoS One. 2007 Oct 3;2(10):e984. doi: 10.1371/journal.pone.0000984. PLoS One. 2007. PMID: 17912361 Free PMC article.
440 results